📣 VC round data is live. Check it out!

Insight Molecular Valuation Multiples

Discover revenue and EBITDA valuation multiples for Insight Molecular and similar public comparables like Korro Bio, Quantum-Si, Diaceutics, Alpha Teknova and more.

Insight Molecular Overview

About Insight Molecular

Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company’s flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx.


Founded

2009

HQ

United States

Employees

49

Financials (LTM)

Revenue: $4M
EBITDA: ($27M)

EV

$156M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Insight Molecular Financials

Insight Molecular reported last 12-month revenue of $4M and negative EBITDA of ($27M).

In the same LTM period, Insight Molecular generated $2M in gross profit, ($27M) in EBITDA losses, and had net loss of ($44M).

Revenue (LTM)


Insight Molecular P&L

In the most recent fiscal year, Insight Molecular reported revenue of $4M and EBITDA of ($26M).

Insight Molecular is unprofitable as of last fiscal year, with gross margin of 57%, EBITDA margin of (646%), and net margin of (1239%).

See analyst estimates for Insight Molecular
LTMLast FY202320242025202620272028
Revenue$4M$4M$2M$2M$4M
Gross Profit$2M$2M$413K$740K$2M
Gross Margin58%57%27%39%57%
EBITDA($27M)($26M)($23M)($59M)($48M)
EBITDA Margin(763%)(646%)(1538%)(3137%)(1182%)
EBIT Margin(1128%)(754%)(1491%)(1236%)(754%)
Net Profit($44M)($50M)($28M)($61M)($50M)
Net Margin(1233%)(1239%)(1848%)(3225%)(1239%)

Financial data powered by Morningstar, Inc.

Insight Molecular Stock Performance

Insight Molecular has current market cap of $164M, and enterprise value of $156M.

Market Cap Evolution


Insight Molecular's stock price is $5.07.

Insight Molecular share price increased by 26.1% in the last 30 days, and by 52.7% in the last year.

Insight Molecular has an EPS (earnings per share) of $-1.56.

See more trading valuation data for Insight Molecular
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$156M$164M1.4%26.1%-15.6%52.7%$-1.56

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Insight Molecular Valuation Multiples

Insight Molecular trades at 44.0x EV/Revenue multiple, and (5.8x) EV/EBITDA.

See NTM and 2027E valuation multiples for Insight Molecular

EV / Revenue (LTM)


Insight Molecular Financial Valuation Multiples

As of May 9, 2026, Insight Molecular has market cap of $164M and EV of $156M.

Insight Molecular has a P/E ratio of (3.8x).

LTMLast FY202320242025202620272028
EV/Revenue44.0x38.4x103.5x82.7x38.4x
EV/EBITDA(5.8x)(5.9x)(6.7x)(2.6x)(3.2x)
EV/EBIT(3.9x)(5.1x)(6.9x)(6.7x)(5.1x)
EV/Gross Profit76.0x67.7xn/m210.3x67.7x
P/E(3.8x)(3.3x)(5.9x)(2.7x)(3.3x)
EV/FCF—(6.1x)(6.6x)(7.3x)(6.1x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Insight Molecular Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Insight Molecular Margins & Growth Rates

Insight Molecular decreased revenue by 36% but EBITDA grew by 9% in the last fiscal year.

In the most recent fiscal year, Insight Molecular reported gross margin of 57%, EBITDA margin of (646%), and net margin of (1239%).

See estimated margins and future growth rates for Insight Molecular

Insight Molecular Margins

Last FY202420252026202720282029
Gross Margin57%39%57%58%
EBITDA Margin(646%)(3137%)(1182%)(1099%)
EBIT Margin(754%)(1236%)(754%)(1188%)
Net Margin(1239%)(3225%)(1239%)(1217%)
FCF Margin(626%)(1129%)(626%)—

Insight Molecular Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(36%)25%116%(36%)
Gross Profit Growth(34%)79%211%(34%)
EBITDA Growth9%155%(19%)(41%)
EBIT Growth1%4%32%1%
Net Profit Growth(37%)118%(17%)(37%)
FCF Growth—(10%)20%—

Data powered by FactSet, Inc. and Morningstar, Inc.

Insight Molecular Operational KPIs

Insight Molecular's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.7M for the same period.

Insight Molecular's Rule of 40 is (1135%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Insight Molecular's Rule of X is (1189%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Insight Molecular
LTMLast FY202320242025202620272028
Rule of 40(734%)(1135%)———
Bessemer Rule of X(691%)(1189%)———
Revenue per Employee—$0.1M———
Opex per Employee—$0.7M———
S&M Expenses to Revenue200%156%21%34%30%
G&A Expenses to Revenue373%367%880%699%367%
R&D Expenses to Revenue429%392%618%523%392%
Opex to Revenue—811%1519%1275%811%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Insight Molecular Competitors

Insight Molecular competitors include Korro Bio, Quantum-Si, Diaceutics, Alpha Teknova, Bioventix, SDI Group, Vitrafy, ArcticZymes, Pacific Edge and 4basebio.

Most Insight Molecular public comparables operate across Life Sciences Tools.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Korro Bio16.0x20.6x(1.2x)—
Quantum-Si30.2x37.9x(0.9x)(0.9x)
Diaceutics4.4x3.7x50.5x19.3x
Alpha Teknova5.3x5.1x(32.0x)(30.2x)
Bioventix6.4x6.6x8.2x8.7x
SDI Group1.7x1.5x9.4x7.8x
Vitrafy2106.7x85.6x(11.1x)(8.1x)
ArcticZymes6.9x6.4x36.2x47.9x

This data is available for Pro users. Sign up to see all Insight Molecular competitors and their valuation data.

Start Free Trial

Insight Molecular Funding History

Before going public, Insight Molecular raised $8M in total equity funding, across 2 rounds.


Insight Molecular Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Jan-20Series A—$5M——
May-15Seed—$3M——

Insight Molecular M&A Activity

Insight Molecular has acquired 1 company to date.

Last acquisition by Insight Molecular was on February 2nd 2021. Insight Molecular acquired Chronix Biomedical for $7M (EV/Revenue multiple of ).

See M&A valuation multiples

Latest Acquisitions by Insight Molecular

Chronix Biomedical
Description
Chronix Biomedical is a San Jose-headquartered biotech firm developing blood-based assays measuring circulating DNA for cancer diagnosis and monitoring. The technology analyzes tumor-specific sequences in plasma to assess treatment response in prostate, breast, and lung cancers. Research collaborations operate from facilities in Hanover, Germany.
HQ CountryUnited States
HQ City
San Jose, CA
Deal Date2 Feb 2021
Valuation$7M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Insight Molecular acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Insight Molecular

When was Insight Molecular founded?Insight Molecular was founded in 2009.
Where is Insight Molecular headquartered?Insight Molecular is headquartered in United States.
How many employees does Insight Molecular have?As of today, Insight Molecular has over 49 employees.
Who is the CEO of Insight Molecular?Insight Molecular's CEO is Joshua Riggs.
Is Insight Molecular publicly listed?Yes, Insight Molecular is a public company listed on Nasdaq.
What is the stock symbol of Insight Molecular?Insight Molecular trades under IMDX ticker.
When did Insight Molecular go public?Insight Molecular went public in 2015.
Who are competitors of Insight Molecular?Insight Molecular main competitors include Korro Bio, Quantum-Si, Diaceutics, Alpha Teknova, Bioventix, SDI Group, Vitrafy, ArcticZymes, Pacific Edge, 4basebio.
What is the current market cap of Insight Molecular?Insight Molecular's current market cap is $164M.
What is the current revenue of Insight Molecular?Insight Molecular's last 12 months revenue is $4M.
What is the current revenue growth of Insight Molecular?Insight Molecular revenue growth (NTM/LTM) is 29%.
What is the current EV/Revenue multiple of Insight Molecular?Current revenue multiple of Insight Molecular is 44.0x.
Is Insight Molecular profitable?No, Insight Molecular is not profitable.
What is the current EBITDA of Insight Molecular?Insight Molecular has negative EBITDA and is not profitable.
What is Insight Molecular's EBITDA margin?Insight Molecular's last 12 months EBITDA margin is (763%).
What is the current EV/EBITDA multiple of Insight Molecular?Current EBITDA multiple of Insight Molecular is (5.8x).
How many companies Insight Molecular has acquired to date?As of May 2026, Insight Molecular has acquired 1 company.
What was the largest acquisition by Insight Molecular?$7M acquisition of Chronix Biomedical on 2nd February 2021 was the largest M&A Insight Molecular has done to date.
What companies Insight Molecular acquired?Insight Molecular acquired Chronix Biomedical.
In how many companies Insight Molecular has invested to date?Insight Molecular hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Insight Molecular

Lists including Insight Molecular

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial